Neurocognitive Disorder Treatment Market report includes historic data, present market trends, environment, technological innovation, upcoming technologies and the technical progress in the related industry. Neurocognitive Disorder Treatment Market offers complete, proficient report delivering market research data that is relevant for new market entrants or set up players. Key strategies of the companies operating in the market and their impact analysis have been included in the report.
Global Neurocognitive Disorder Treatment Market
Neurocognitive disorders generally include dementia, delirium, and mild cognitive impairment, which is characterized by a major decline in the level of cognitive functioning. Neurocognitive deficit is a reduction or impairment of cognitive functions and affects nerve cells and often impact the person’s ability to remember, to reason, and to make judgments.
Get Your FREE Sample Copy of the Neurocognitive Disorder Treatment Market Report 2021
Neurocognitive disorders feature a plethora of clinical characteristics with Alzheimer disease, front temporal degeneration, cerebrovascular disease, traumatic brain injury, Lewy body disease, and infections showing the common causes. Alzheimer disease is the most common cause of neurocognitive disorder. In the early stages of Alzheimer, people are not able to remember the recent events, conversations, and names of people and may also experience the depression. Individuals with neurocognitive disorder show the side effects like mood disturbances including apathy, depression, anxiety and sleep disturbance including insomnia, hypersomnia.
The most widely known neurocognitive disorder treatments include pain medications, surgeries, physical therapy, bed rest, and numerous others. Furthermore, antibiotics are extensively used for treatment of neurocognitive disorder, in order to eliminate the remaining infections, which eventually affect the brain, for example, meningitis.
Global Neurocognitive Disorder Treatment Market Dynamics
Increasing prevalence of neurocognitive disorder is expected to augment the global neurocognitive disorder treatment market growth. Due to advancement in technology and inventions such as Al and adoption of unhealthy work practices, increased cardiovascular issues are boosting the global neurocognitive disorder market. Moreover, increased addiction of drugs and alcohol among the youth and changing climatic conditions or respiratory diseases are leading to neurocognitive disorders worldwide, and therefore driving the global market growth. Furthermore, increase in number of geriatric population is also the factor affecting the market growth. Approvals of the drugs associated with the treatment from the regulatory bodies is the factor that drives the market growth. For instance, on April 11, 2019, the U.S.FDA accepted the resubmitted new drug application (NDA) for instradefylline (KW-6002), which is an oral selective adenosine receptor antagonist for use as adjunctive treatment for Parkinson’s disease in adults. On May 20, 2019, the U.S.FDA approved Neuronascent Investigational New Drug (IND) application for NNI-362.
Buy Now This Premium Report to Grow your Business: https://www.coherentmarketinsights.com/insight/buy-now/2676
Reasons to Purchase this Report
• Current and future of global Neurocognitive Disorder Treatment market outlook in the developed and emerging markets
• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
• Regions/countries that are expected to witness the fastest growth rates during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players
“Limited Time Offer”
Access insightful study with over 150+ pages, list of tables & figures, profiling 20+ companies.
We also offer 15% FREE Report customization.
Get This premium report with Instant US$ 2000 discount @ https://www.coherentmarketinsights.com/promo/buynow/2676
The clinical trials of some drugs are terminated, as they are not able to reach to their primary endpoint. For instance, on March 21, 2019, Biogen and Eisei, Co., Ltd announced the decision to discontinue the global phase 3 trial of Aducanumab, which is designed to evaluate the safety and efficacy of an antibody-aducanumab in patients with Alzheimer disease. This decision to stop the trial is based on the analysis that trials were unlikely to improve the people’s memory and thinking sufficiently by the end of the trial. This discontinuation of trials thus acts as a major restraining factor for the global market growth.
Global Neurocognitive Disorder Treatment Market – Regional Dynamics
North America is expected to hold a dominant position in the global neurocognitive disorder treatment market, owing to adoption of advanced technology and rising number of neurocognitive disorder patients. According to the World Health Organization (WHO), nearly 35.6 million people live with dementia worldwide. The number of geriatric population worldwide and related dementia patients is expected to rise up to 65.7 million in 2030 and 115.4million in 2050. Furthermore, according WHO, the prevalence of dementia is increasing exponentially with age and sex in North America region, doubling in every 5.5 years. Moreover, satisfactory reimbursement policies, rising adoption of advance precautious methods and increasing penetration of life science analytics for monitoring health changes continuously are the most prominent factors driving the North America market growth.
Global Neurocognitive Disorder Treatment Market – Competitive Backdrop
The renowned players operating in the global neurocognitive disorder treatment market are A B Science, Abbive, A C immune, Biogen, Eisai, Immunobrain, Mediti Pharma Inc., Ono Pharmaceuticals, Proclar Biosciences, Problodrug AG, Roche, T3D Therapeutics, and Purdue Pharma. These companies are further focusing on the formulation of new, efficient neurocognitive disorder treatment drugs in a bid to meet the rising demand for various types of neurocognitive disorder treatments. For instance, in March 2018, Biogen announced to enter into an agreement to acquire Pfizer Inc. phase 2b ready AMPA receptor potentiator for cognitive impairment. Furthermore, in May 2019, T3D therapeutics received grant of US$ 9 million from National Institute on Aging (NIA) to develop drug T3D-959 for neurocognitive disease.
Ask for PDF sample copy of the Neurocognitive Disorder Treatment market report @ https://www.coherentmarketinsights.com/insight/request-pdf/2676
Market Taxonomy
Based on the disorder type:
- Alzheimer Disease
- Dementia
- Parkinson’s Disease
- Huntington’s Disease
- Others
On the basis of treatment type:
- Cholinesterase Inhibitors
- N-methyl-D Aspartate Receptor Antagonists
- Others
By distribution channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
Major Point Answered in Neurocognitive Disorder Treatment Market Research Study are: –
• What will the market growth rate, Overview, and Analysis by Type of Neurocognitive Disorder Treatment market be in 2026?
• What are the key factors driving, Analysis by Applications and Countries Neurocognitive Disorder Treatment market?
• What are Dynamics, This Overview Includes Analysis of Scope and price analysis of top Manufacturers Profiles of Neurocognitive Disorder Treatment market?
• Who are the Opportunities, Risk, and Driving Force of the Neurocognitive Disorder Treatment market? Knows Upstream Raw Materials Sourcing and Downstream Buyers
• Who are the key vendors in the Neurocognitive Disorder Treatment market space? Business Overview by Type, Applications, Gross Margin and Market Share
• What are the Neurocognitive Disorder Treatment market opportunities and threats faced by the vendors in the market?
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837